Filing Flows

Filing Flows › Companies › Treace Medical Concepts › Report card

Treace Medical Concepts earnings report card

Every report on file against what analysts and the company itself expected, and what the stock did

Beat rate5 of 5 reports beat the EPS estimate

Treace Medical Concepts (TMCI) beat the analysts' EPS estimate in 5 of its last 5 reports (100%), by +39.6% on average.

Beat rate100% of 5
Average surprise+39.6%

Report by report

QuarterReportedEPS est.EPS reportedSurpriseRevenue reported
Q3 2026Nov 6, 2026−$0.25−$0.15+39.8%$48.3M
Q2 2026Aug 7, 2026−$0.30−$0.20+33.3%$45.4M
Q1 2026May 8, 2026−$0.31−$0.12+62.8%$47.2M
Q4 2025Feb 27, 2026−$0.14−$0.08+44.1%$62.5M
Q3 2025Nov 6, 2025−$0.27−$0.22+18.2%$50.2M

Estimates and reported EPS are the Street's adjusted figures. Revenue reported is from the company's filing. No daily prices are on file for these report days, so the stock's moves are not shown.

Charts

Treace Medical Concepts: EPS reported against the estimateTreace Medical Concepts: EPS reported against the estimateEstimateReported−$0.27−$0.22Q3 2025−$0.14−$0.08Q4 2025−$0.31−$0.12Q1 2026−$0.30−$0.20Q2 2026−$0.25−$0.15Q3 2026
Latest (Q3 2026): Estimate −$0.25, Reported −$0.15.

The next report: what to expect → Treace Medical Concepts: every quarter →

Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.